Corticosteroid use to mitigate transaminitisassociated decline in FVIII levels following valoctocogene roxaparvovec gene therapy clinical practice guidance

Abstract

Description

Keywords

Citation

WOS

Endorsement

Review

Supplemented By

Referenced By